MS-DRG v44.0 · MDC 17: Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms
850 — Acute Leukemia with Other Procedures
Source: CMS MS-DRG v44.0 and FY2027 IPPS final rule. Page updated September 29, 2026.
- Relative weight
- 8.4113
- Geometric mean LOS
- 15.6 days
- Arithmetic mean LOS
- 23.2 days
- Type
- Surgical
About MS-DRG 850
MS-DRG 850, Acute Leukemia with Other Procedures, is a surgical DRG in MDC 17 (Myeloproliferative Diseases and Disorders, Poorly Differentiated Neoplasms) under MS-DRG version 44.0, which applies to inpatient discharges from October 1, 2026 through September 30, 2027.
Its FY2027 relative weight is 8.4113, so Medicare's base payment for this DRG is about 8.41 times the average inpatient case, before hospital-specific adjustments. The geometric mean length of stay is 15.6 days and the arithmetic mean is 23.2 days.
33 ICD-10-CM diagnosis codes are part of this DRG's grouping logic; they are listed below.
ICD-10-CM codes that group to DRG 850 (33)
Chapter 2: Neoplasms
- C91.00Acute lymphoblastic leukemia not having achieved remission
- C91.01Acute lymphoblastic leukemia, in remission
- C91.02Acute lymphoblastic leukemia, in relapse
- C92.00Acute myeloblastic leukemia, not having achieved remission
- C92.01Acute myeloblastic leukemia, in remission
- C92.02Acute myeloblastic leukemia, in relapse
- C92.40Acute promyelocytic leukemia, not having achieved remission
- C92.41Acute promyelocytic leukemia, in remission
- C92.42Acute promyelocytic leukemia, in relapse
- C92.50Acute myelomonocytic leukemia, not having achieved remission
- C92.51Acute myelomonocytic leukemia, in remission
- C92.52Acute myelomonocytic leukemia, in relapse
- C92.60Acute myeloid leukemia with 11q23-abnormality not having achieved remission
- C92.61Acute myeloid leukemia with 11q23-abnormality in remission
- C92.62Acute myeloid leukemia with 11q23-abnormality in relapse
- C92.A0Acute myeloid leukemia with multilineage dysplasia, not having achieved remission
- C92.A1Acute myeloid leukemia with multilineage dysplasia, in remission
- C92.A2Acute myeloid leukemia with multilineage dysplasia, in relapse
- C93.00Acute monoblastic/monocytic leukemia, not having achieved remission
- C93.01Acute monoblastic/monocytic leukemia, in remission
- C93.02Acute monoblastic/monocytic leukemia, in relapse
- C94.00Acute erythroid leukemia, not having achieved remission
- C94.01Acute erythroid leukemia, in remission
- C94.02Acute erythroid leukemia, in relapse
- C94.20Acute megakaryoblastic leukemia not having achieved remission
- C94.21Acute megakaryoblastic leukemia, in remission
- C94.22Acute megakaryoblastic leukemia, in relapse
- C94.40Acute panmyelosis with myelofibrosis not having achieved remission
- C94.41Acute panmyelosis with myelofibrosis, in remission
- C94.42Acute panmyelosis with myelofibrosis, in relapse
- C95.00Acute leukemia of unspecified cell type not having achieved remission
- C95.01Acute leukemia of unspecified cell type, in remission
- C95.02Acute leukemia of unspecified cell type, in relapse
Common questions about DRG 850
What is the relative weight of DRG 850?
- 8.4113 for FY2027 (MS-DRG v44.0), from the IPPS final rule Table 5.
What is the average length of stay for DRG 850?
- The geometric mean length of stay is 15.6 days; the arithmetic mean is 23.2 days.
Is DRG 850 medical or surgical?
- DRG 850 is a surgical DRG.